The Chris Elliott Fund Commends New Bill to Improve Access to Oral Chemotherapy Drugs

New legislation in the House of Representatives, HR 1801, The Cancer Drug Coverage Parity Act seeks to require insurance companies to cover all intravenous and oral chemotherapy forms equally, potentially broadening access and availability to patients who need it.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
There are so many great treatments out there and unfortunately too often brain cancer patients are left with the question of who is going to pay for it

Seattle, WA (PRWEB) May 13, 2013

The Chris Elliott Fund commends the work of Congressman Brian Higgins, NY-26 , for introducing the Cancer Drug Coverage Parity Act which would require health insurance companies to equally cover and reimburse intravenous/injectable and orally administered anti-cancer medication. “Doctors, not insurance companies, should decide the best course of treatment for cancer patients. This legislation will better enable patients access to the best available treatments that will extend and improve their quality of life” said Higgins in a press release on the introduction of the act on May 2nd 2013.

Many brain tumor patients face mounting costs throughout treatment, one of which can be oral chemo therapy treatment. “There are so many great treatments out there and unfortunately too often brain cancer patients are left with the question of who is going to pay for it” says Dellann Elliott Mydland, Chris Elliott Fund Founder & President, “it is unfortunate to see individuals and families bankrupted by cancer care and treatment, and this Act aims to change that.” The Chris Elliott Fund supports this bill and offers that it is a great bridge between science and healthcare, finding affordable solutions for the care people need. It is part of CEF's mission to provide immediate equal access to advance treatment, in hopes to end brain cancer. Financial concerns are a specific focus of The Chris Elliott Fund, earlier this year the organization hosted a 2-part webinar in their Brains Matter Webinar Series on “A Brain Tumor Patient’s Guide to Insurance & Financial Resources”. For updates on webinars and educational information, or to follow news on this Act email the Chris Elliott Fund at WeCare(at)EndBrainCancer(dot)com.

About the Chris Elliott Fund:
The Chris Elliott Fund (CEF) is a patient advocacy organization and national 501(c)(3) non-profit with corporate offices in Seattle, Washington, with goals to end brain cancer through education, advocacy, awareness and support. Established in 2002, CEF has grown to provide support nationally for brain cancer and brain tumor patients seeking guidance, advice, and assistance to demystify finding the absolute best course of treatment for their brain cancer or brain tumor. The organization and its advocates, on average, serve 500-800 patients and caregivers per month, free of charge. If we can help, please contact us at WeCare(at)EndBrainCancer(dot)com.


Contact

  • Rachel Tougher
    Chris Elliott Fund
    253-651-5331
    Email
Follow us on: Contact's Facebook Contact's Twitter Contact's LinkedIn